Phase II single arm trial of VEGF Trap [aflibercept] in patients with recurrent temozolomide-resistant malignant gliomas

Trial Profile

Phase II single arm trial of VEGF Trap [aflibercept] in patients with recurrent temozolomide-resistant malignant gliomas

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Anaplastic astrocytoma; Astrocytoma; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 27 Jun 2017 Converging evidence from 5 seperate phase II trials (NCT00035656, NCT00345163, NCT00704288, NCT00369590 and NTR1929) results published in the Clinical cancer research: an official journal of the American Association for Cancer Research
    • 10 Jun 2017 Biomarkers information updated
    • 08 Apr 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top